Stepan Company (SCL) Q2 2025 earnings summary

Executive summary

• Q2 2025 net income rose 19% year-over-year to $11.3 million; adjusted net income up 27% to $12.0 million, driven by Polymers, Crop Productivity, and a lower tax rate.

• Adjusted EBITDA for Q2 2025 was $51.4 million, up 8% year-over-year, with global sales volume up 1%.

• Free cash flow was negative $14.4 million due to higher working capital, inventory builds ahead of tariffs, and safety stock for hurricane season and labor agreements.

• Pasadena, Texas alkoxylation site is operational, with $6.1 million in start-up and remediation costs impacting Q2; expected to drive specialty alkoxylation growth in H2 2025 and beyond.

• Sale of Philippines assets is on track for Q4 2025 close; ongoing asset optimization and strategic investments continue.

Financial highlights

• Q2 2025 net sales increased 7% year-over-year to $594.7 million, mainly from higher selling prices and favorable product mix.

• Adjusted net income for Q2 was $12.0 million ($0.52 per share), up 27% year-over-year.

• Adjusted EBITDA: $51.4 million, up 8% from $47.7 million year-over-year.

• Cash from operations was $11.2 million; capital expenditures for Q2 2025 were $25.6 million.

• Net debt at June 30, 2025 was $569.1 million, with a net debt to capitalization ratio of 31%.

Outlook and guidance

• Pasadena alkoxylation facility is expected to drive volume growth and supply chain savings in H2 2025 and beyond.

• Management expects continued growth in Surfactants' key end markets and improving Polymer demand as market certainty increases.

• 2025 capital expenditures are forecasted at $120–$125 million; effective tax rate expected at 22–24%.

• Asset sale in the Philippines is on track to close in Q4 2025; focus remains on optimizing global footprint.

• Management remains optimistic for full-year adjusted EBITDA, adjusted net income growth, and positive free cash flow in 2025.